Effect of treatment with GLP-1R agonists on the urinary peptidome
of T2DM patients
Sonnal
Lohia1,2,
Justyna Siwy3, Emmanouil
Mavrogeorgis2,3, Susanne Eder4,
Stephanie Thoeni4, Gert Mayer4,
Harald Mischak3, Antonia Vlahou1 and
Vera Jankowski2*
1Center of Systems Biology, Biomedical Research
Foundation of the Academy of Athens, 11527 Athens, Greece;
slohia@bioacademy.gr (S.L.); vlahoua@bioacademy.gr (A.V.)
2Institute for Molecular Cardiovascular Research, RWTH
Aachen University Hospital, 52074 Aachen, Germany;
mavrogeorgis@mosaiques.de (E.M.); vjankowski@ukaachen.de (V.J.)
3Mosaiques Diagnostics GmbH, 30659 Hannover, Germany;
siwy@mosaiques-diagnostics.com (J.S.); mischak@mosaiques.de (H.M.)
4Department of Internal Medicine IV (Nephrology and
Hypertension), Medical University Innsbruck, 6020 Innsbruck, Austria;
susanne.eder@i-med.ac.at (S.E.); stefanie.thoeni@i-med.ac.at (S.T.);
gert.mayer@i-med.ac.at (G.M.)
*Correspondence: vjankowski@ukaachen.de; Tel.: +49-(0241)-80-80580; Fax:
+49-0241